Investor Relations

Listed On The Shanghai Stock Exchange In June 2001, With A Maximum Market Value Of 47.5 Billion

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Resolutions of 2022 Annual General Meeting

Time:2023-06-09

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Company’s Drug Passing the Consistency Evaluation of Generic Drugs

Time:2023-06-07

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Resolutions of 2023 First Extraordinary General Meeting

Time:2023-05-19

Ad hoc announcement pursuant to Art. 53 LR-JCARE Notice of 2022 Annual General Meeting

Time:2023-05-17

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining the Certificate of Invention Patent

Time:2023-05-10

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining Drug Registration for Triptorelin Acetate Microspheres for Injection

Time:2023-05-10

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Approval for Additional Indications of Tocilizumab Injection

Time:2023-05-07

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Receipt of Registration Approval for an Additional Indication of Ilaprazole Sodium for Injection

Time:2023-05-07

Ad hoc announcement pursuant to Art. 53 LR-JCARE Notice of 2023 First Extraordinary General Meeting

Time:2023-04-28

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Proposed Cancellation of Treasury Shares Previously Repurchased

Time:2023-04-28

< 1...121314...16 >